Hypertension, living kidney donors, and transplantation: where are we today?

Area of Science:

• Nephrology
• Cardiology
• Transplantation Immunology

Background:

• Hypertension is a significant complication in kidney transplant recipients.
• It acts as a traditional risk factor for atherosclerotic cardiovascular disease, leading to premature allograft failure and mortality.
• Factors influencing hypertension include donor characteristics, peritransplant events, and recipient-specific variables.

Purpose of the Study:

• To review the multifaceted causes and management strategies for hypertension in kidney transplant recipients.
• To explore the impact of immunosuppressive therapies and other factors on post-transplant blood pressure.
• To discuss pharmacologic approaches for blood pressure control and their effects on graft function and patient survival.

Main Methods:

• Literature review of studies on hypertension in kidney transplant recipients.
• Analysis of the role of immunosuppressive agents, particularly calcineurin inhibitors, in causing hypertension.
• Evaluation of the impact of specific antihypertensive medications and other factors like living donation on blood pressure control and graft outcomes.

Main Results:

• Calcineurin inhibitors are a major cause of hypertension due to endothelial dysfunction and sodium retention.
• Blood pressure control is inversely related to estimated glomerular filtration rate (GFR).
• Dihydropyridine calcium channel blockers may improve GFR, while ACE inhibitors/ARBs are generally avoided early post-transplant.

Conclusions:

• Effective hypertension management is crucial for improving outcomes in kidney transplant recipients.
• Medication choice, including the use of newer agents like belatacept and beta-blockers, impacts blood pressure and patient survival.
• Addressing factors like transplant renal artery stenosis and considering donor characteristics are vital for comprehensive care.